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Abstract 
Background: Malaria continues to be a major burden in the endemic regions of Kenya. Health outcomes associated 
with case management are dependent on the use of appropriate diagnostic methods. Rapid diagnostic tests (RDTs) 
have provided an important tool to help implement the WHO recommended parasite-based diagnosis in regions 
where expert microscopy is not available. One of the questions that must be answered when implementing RDTs is 
whether these tests are useful in a specific endemic region, as well as the most appropriate RDT to use. Data on the 
sensitivity and specificity of RDT test kits is important information to help guide test selection by national malaria 
control programmes.
Methods: This study evaluated the diagnostic performance of RDTs including First Response (FR), CareStart (CS), 
SD Bioline (SD), and Binax Now (BN). The performance of these malaria kits was compared to microscopy, the gold 
standard, for the detection of malaria parasites. The malaria RDTs were also compared to PCR which is a more sensitive 
reference test. Five-hundred participants were included in the study through community screening (50 %) and testing 
suspected malaria cases referred from health facilities.
Results: Of the 500 participants recruited, 33 % were malaria positive by microscopy while 51.2 % were positive by 
PCR. Compared to microscopy, the sensitivity of eight RDTs to detect malaria parasites was 90.3–94.8 %, the specificity 
was 73.3–79.3 %, the positive predictive value was 62.2–68.8 %, and the negative predictive value was 94.3–96.8 %. 
Compared to PCR, the sensitivity of the RDTs to detect malaria parasites was 71.1–75.4 %, the specificity was 80.3–
84.4 %, the positive predictive value was 80.3–83.3 %, and the negative predictive value was 73.7–76.1 %. The RDTs 
had a moderate measure of agreement with both microscopy (>80.1 %) and PCR (>77.6 %) with a κ > 0.6.
Conclusion: The performance of the evaluated RDTs using field samples was moderate; hence they can significantly 
improve the quality of malaria case management in endemic regions in Kenya by ensuring appropriate treatment of 
malaria positive individuals and avoiding indiscriminate use of anti-malarial drugs for parasite negative patients.
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Background
Malaria continues to be a life-threatening illness in Kenya 
[1]. Early and reliable parasite-based diagnosis, treat-
ment and other malaria control programs such as use of 
insecticide treated bed-nets and indoor residual spray 
are key to reducing malaria incidence in Kenya, which 
occurs principally in the Lake Victoria region. An addi-
tional driver for accurate laboratory diagnosis is the 
increasing incidence of Plasmodium falciparum resist-
ance to common anti-malarial drugs, which necessitates 
the use of more expensive and potentially cost-prohibi-
tive combination therapy [2]. The World Health Organi-
zation (WHO) emphasizes diagnosis of malaria prior to 
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treatment to avoid indiscriminate use of anti-malarials. 
However, presumptive treatment of all fevers, such as 
malaria, is still popular in resource-poor settings due to 
lack of effective laboratory infrastructure and techni-
cal expertise. In these resource-limited settings, empiri-
cal treatment often results in overuse of anti-malarial 
drugs and delays in the diagnosis of other life-threatening 
febrile illness [3, 4].
The commonly accepted diagnostic method for detect-
ing malaria is microscopic examination of Giemsa-
stained blood films. In expert hands, microscopy is highly 
sensitive (lower limit of parasites down to ~0.0001  % 
parasitaemia), and very specific. Microscopy can deter-
mine the species and stage of circulating parasites, along 
with parasitaemia to provide data for disease prognosis 
and monitoring response to treatment [5]. Microscopic 
examination of thin and thick smears is highly depend-
ent on the microscopist’s skills and requires blinded con-
firmatory readings to ensure the findings are confirmed. 
In local laboratories and clinical facilities with or without 
expert microscopists, the reported results are often vari-
able. In many African countries, malaria expert micros-
copists are scarce, and microscopy data are often of poor 
quality. The poor microscopy results are due to a host of 
factors such as slide preparation techniques, the quality 
of essential laboratory supplies, condition of the micro-
scope, workload, lack of training, and skills maintenance 
[5]. Polymerase chain reaction (PCR) methods can be 
relied upon in the detection of submicroscopic and 
microscopic parasites with high sensitivity and specific-
ity. A highly sensitive qRT-PCR has a limit of detection 
of 0.002 P/µL while microscopy has limit of detection of 
100 P/µL [6]. Most qPCR methods target different genes 
in the parasite genome with most detecting 18S-rRNA, 
although there are many other non-18S-rRNA-qPCR 
methods being developed. Despite the high performance 
of PCR, it has several disadvantages in that it is time con-
suming and requires training because of the procedures 
involved, furthermore it’s expensive because of the rea-
gents and complex equipment required to run the assay 
[7].
The introduction of malaria rapid diagnostic tests 
(RDTs) has enhanced quick examination of blood sam-
ples from suspected malaria patients. However, it is not 
clear which RDT is the most appropriate in different 
endemic areas with mono and mixed infections of dif-
ferent parasites. RDTs detect Plasmodium parasites by 
an antigen–antibody reaction. The antigens detected 
in blood include Plasmodium lactate dehydrogenase 
(pLDH), histidine-rich protein II (HRP-2), and Plasmo-
dium aldolase [5]. Those that target HRP-2 detect only 
P. falciparum while those that target pLDH and aldolase 
antigens can detect non-falciparum infections. Regard-
less of the setting, RDTs require minimal operator train-
ing, and yield highly reproducible test interpretations. 
RDT results are normally rapidly available when the 
physician is actively managing patients as the test can 
be completed in less than 20  min. They do not require 
any instrumentation, electricity, special laboratories, 
or water and these kits are generally cost-beneficial as 
they provide accurate diagnosis of disease quickly. Rapid 
diagnosis of disease avoids the consequences of missed 
diagnoses of malaria, overuse of anti-malarial, and the 
possible missed diagnosis of another febrile illness. Dif-
ferences in sensitivity and specificity among RDTs have 
been reported due to several possible reasons, including 
exposure to high temperatures and humidity that cause 
denaturation of antibodies, HRP-2 gene polymorphisms 
and deletions, operational difficulties, and human error 
[8].
National policy guidelines for malaria diagnosis in 
Kenya clearly articulate the role of RDTs as part of effec-
tive malaria case management. The Government has 
procured RDTs in support of its parasite-based diagno-
sis policy. These RDTs were procured to be used as the 
primary method for malaria diagnosis in dispensaries 
and health centres in Kenya [9]. However, the prevalence 
of malaria is different in various regions of Kenya, and 
these regional differences may affect the diagnostic per-
formance of a test. Differences in prevalence are brought 
about by clinical variability which reflects the differences 
in patient presentation, including high or low disease 
incidence. All of these variables can cause differences in 
sensitivity and specificity of a diagnostic test [10]. There 
are other variables that can influence the performance 
of RDTs in different regions, such as population differ-
ences, differences in the characteristics and genetic vari-
ation of the malaria parasite, and diagnostic practice and 
skills [11]. The successful use of RDTs in different parts 
of Kenya depends on selecting the best RDT for that par-
ticular region. Minimizing the number of false positives 
and false negatives is clearly of great importance when 
selecting the most appropriate RDT. Lack of resources 
limits countries from performing adequate evaluations 
of RDTs, which can lead to deploying diagnostic tests in 
geographic areas where their performance is not assured. 
Evaluations of RDTs for a specific region will help 
reduce the financial cost associated with their failure in 
malaria control programmes. Therefore, in order to assist 
National Malaria Control Programmes in selection of 
products for specific regions, four kinds of commercially 
available RDTs were evaluated in terms of their diagnos-
tic performance against gold standard method, micros-
copy of Giemsa-stained blood smears.
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Methods
Study area
The study was conducted in the Kombewa Clinical 
Research Centre (CRC) (Fig.  1), situated 40  km west 
of Kisumu city, as part of the Kombewa Health and 
Demographic Surveillance System (HDSS). The site 
lies between longitudes 34°24′00″E and 34°41′30″E, and 
latitudes 0°11′30″ N and 0°11′30″S, at an average alti-
tude of 1400 m above sea level. Malaria is holoendemic 
in this area, and transmission occurs throughout the 
year. The long rainy season from late March to May pro-
duces intense transmission from April to August. The 
short rainy season from October to December produces 
another, somewhat less intense, transmission season 
from November to January [12]. The area has a total of 
37 sub-locations and 357 villages. The Kombewa CRC 
is in close proximity to 24 functioning health facilities, 
20 of which are government-owned and four private or 
faith-based organizations. The HDSS currently moni-
tors a population of 141,956 individuals drawn from 
34,718 households [12]. The HDSS population is pri-
marily young, with a mean age of 23  years and 48  % of 
the population is below the age of 15 years. The age and 
sex structure has a predominance of young people at the 
base, and a dearth of older age groups. In 2013, a total 
of 33,972 cases of illness were reported, a number which 
represents 24  % of the population. Among these cases, 
children below the age of 5 years accounted for 27 % of all 
reported illness. The most prevalent symptoms recorded 
in the HDSS population were fever (35  %), cold/flu 
(20 %), cough (18 %), diarrhoea and vomiting (9 %).
Study design and sampling
The study was conducted between 2013 and 2014 to 
assess the performance of BinaxNow (Binax Inc, Inver-
ness Medical, ME, USA), SD Bioline (Standard Diagnos-
tics Inc, Korea), Carestart (Access Bio Inc, Monmouth, 
USA), and First Response (Premier Medical Co Ltd, 
India). (1) BinaxNow, which targets both P. falciparum-
specific HRP2 and a pan-malarial antigen, Plasmodium 
aldolase; (2) SD Bioline 05FK50, which targets P. falci-
parum-specific HRP2 only and 05FK60, which targets 
both P. falciparum-specific HRP2 and the pan-malaria 
antigen pLDH; (3) Carestart IFU G0131, which targets 
both P. falciparum-specific HRP2 and the pan malarial 
antigen, pLDH, IFU G0141, which targets P. falciparum-
specific HRP2 only and IFU G0181, which targets both 
P. falciparum-specific HRP2 and pLDH; and, (4) First 
Response I13FRC, which targets P. falciparum-specific 
HRP2 and First Response I16FRC, which targets both P. 
falciparum-specific HRP2 and the pan-malarial antigen 
pLDH.
Fig. 1 Map of the study area HDSS; also showing the study site (Kombewa CRC)
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Participants were recruited to the study through the 
Kombewa HDSS. All patients, irrespective of their age 
and gender, presenting at the health facilities with a clini-
cal suspicion of malaria were included in the study after 
taking written informed consent. The study design was in 
compliance with the STARD methodological guidelines 
for presentation of diagnostic studies [13].
Data collection
Data were collected using register forms and laboratory 
registry notebooks. Intensive training of the study per-
sonnel and supervisors was conducted to ensure proper 
performance of RDT testing and malaria microscopy. 
Blood specimen from the participants was screened 
using selected RDTs, and thin and thick blood films 
were prepared for microscopic examination. All RDTs 
and blood films for a specific blood specimen were given 
identical codes for later comparison of the results. Each 
RDT was performed using the manufacturer’s recom-
mended procedures and results were read between 15 
and 20 min while the microscopy films were kept for later 
examination.
Rapid diagnostic test interpretation
RDTs contain a nitrocellulose strip with a labeled mon-
oclonal antibody specific for the antigens and are pre-
coated with monoclonal antibodies for the test strips 
and the control line [8]. The interpretation of the results 
involves the following: for those RDTs detecting HRP2 
and pan antigens, three colour bands (bands in the con-
trol area, P. falciparum area, and pan area) indicated a 
positive result for P. falciparum or mixed infection. For 
those detecting HRP2 alone, two bands (one band in the 
control area and another band in the P. falciparum area 
alone) indicated a positive result for P. falciparum. When 
there was only one band in the control area within the 
result window, this indicated a negative result and the 
test were deemed invalid if the line in the control area did 
not appear. Results were recorded using the participants 
code ID.
Comparison with Giemsa/microscopy
The microscopic examination of blood films is still a gold 
standard for the diagnosis of malaria. It has the ability 
to detect presence or absence of Plasmodium parasites 
by assessing the parasites morphological characteristics 
and correctly specify the infecting Plasmodium spe-
cies [14]. In this study, thick and thin blood films were 
prepared, stored in slide boxes, and transported to the 
Malaria Diagnostic Centre for parasite investigations. 
The thin and thick blood films were examined at 1000× 
magnification and results were reported using stand-
ard operating procedures [15]. Each blood film was read 
by two blinded microscopists and if the results showed 
a discrepancy, a third reading was performed by a third 
microscopist on the discordant results only. The inde-
pendent microscopists were blinded in order to assure 
quality of the microscopic examinations. During slide 
examination, a slide was regarded as negative after exam-
ining 200 high-power fields without finding any parasite. 
A slide was considered positive if at least one asexual 
form of parasite was detected in 100 microscopic fields in 
thick blood film [16]. If a slide was Plasmodium-positive, 
asexual parasites were counted using standard operating 
procedures of light microscopy as recommended by the 
WHO. The number of asexual parasites per 200 white 
blood cells (WBCs), or 500 WBCs for low density infec-
tions, were used to compute the number of asexual para-
sites per μL of blood, assuming a standard count of 8000 
WBCs per μL of blood [15]. Performance of RDTs was 
compared against Giemsa/microcopy results.
Real‑time PCR
The QIAamp DNA Blood Mini Kit (Qiagen, Valencia, 
CA) was used to extract genomic nucleic acids from 
whole/frozen blood samples. Amplification and real-time 
measurements was performed in the Applied Biosystems 
7500 analytical PCR system (Life technologies Grand 
Island, NY, USA). The thermal profile for qPCR was: 
Reverse Transcription step of 30 min at 50 °C, denatura-
tion step of 10 min at 95  °C and 40 cycles of amplifica-
tion for 15 s at 95  °C, and annealing for 1 min at 60  °C. 
For the reaction, 1  µl of template was added to 9  µl of 
reaction master mix (5 µL 2× Quantitect Mix (QIAgen), 
4 mM MgCl2, 0.1 µL Reverse Transcription mix 0.4 µM 
each primer, 0.2  µM probe, and 1.1  µL water). Plasmo-
dium falciparum standard curves and positive controls 
were developed from cultured NF54 parasites while 
nuclease free water was used as negative control (Life 
Technologies, Grand Island, NY, USA). The forward 
primer sequence was 5′-GCTCTTTCTTGATTTCTTG-
GATG-3′, and the reverse primer sequence was 5′-ATG-
GCCGTTTTTAGTAAGATCTCGTTCG-3′. The probe 
sequence was 5′-ATGGCCGTTTTTAGTTCGTG-3′ 
labeled with reporter dye (5′FAM;-6-carboxyfluorescein) 
and quencher dye (3′TAMRA:-6-carboxytetramethyl-
rhodamine). Primer sets were designed based on highly 
conserved Plasmodium genus sequence (18  s rRNA) so 
as to amplify all units of rRNA distributed in all chro-
mosomes: 1, 5, 7, 11 and 13. Primer3 v.0.4.0 web based 
software (http://frodo.wi.mit.edu/primer3/) was used to 
design the primers.
Data analysis
Data were recorded on register forms and entered in a 
Microsoft Excel database (Microsoft Corp, Redmond, 
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Washington, USA) in a secure computer at the Malaria 
Diagnostics Centre. The sensitivity, specificity and predic-
tive values [calculated with 95 % confidence interval (CI)] 
of the RDTs compared to Giemsa microscopy and RT-PCR 
as the reference methods for Plasmodium parasite detec-
tion. Graph Pad Prism v5.01 (Graph Pad Software, CA, 
USA) utilizing the two-tailed Fisher’s exact test was used 
for analysis. Inter-test agreement for both results of posi-
tive and negative readings was expressed by the percentage 
of overall agreement and kappa statistic (κ) for the agree-
ment between malaria RDTs and the reference methods.
Results
Characteristics of study participants
Evaluation of BinaxNow, SD Bioline, Carestart, and First 
Response was based on 500 study participants recruited 
through the Kombewa HDSS via community screen-
ing (~50  %) and suspected malaria cases referred from 
health facilities. The study participants included chil-
dren <12 years (58 %, n = 290), and the remainder were 
ranged in age from 13 to 64 years (42 %, n = 210). The 
male participants were a minority of participants (36 %, 
n  =  181) while the majority of the participants were 
female (64 %, n = 319). Adult women who were not preg-
nant comprised 39  % of the female population (39  %, 
n  =  196), one was pregnant, and the remainder were 
children. The number of Plasmodium-positive cases was 
33  % (166/500) by the gold standard Giemsa/micros-
copy, while 51  % (256/500) were positive by RT-PCR. 
The eight RDTs detected 44–48 % malaria positive cases 
and 52–56 % malaria negative cases (Table 1). Of the 166 
microscopy positive cases, 84  % (139/166) were P. falci-
parum, and 13 % (22/166) were mixed species of P. falci-
parum and Plasmodium malariae. 
Performance of eight malaria RDTs as compared to the 
gold standard Giemsa/microscopy
The sensitivity and specificity of RDTs to detect P. falci-
parum (HRP2-band) against microscopy was relatively 
similar across all the eight malaria RDTs tested. The 
sensitivity was shown to be  >90  % while the specificity 
was shown to be >73 % when compared to microscopy. 
The SD Bioline 05FK50 kit had the highest sensitivity of 
94.8 % (89.9–97.7) while First Response I16FRC kit had 
the lowest sensitivity of 90.4 % (84.8–94.4). The specific-
ity of all the eight malaria kits was >73 % when compared 
to microscopy. The BinaxNOW 665-025 kit had the high-
est specificity of 79.3  % (74.6–83.6) while SD Bioline 
05FK50 kit had the lowest specificity of 73.3  % (68.1–
77.9) (Table 2).
The eight malaria RDTs had a positive predictive 
value of >62 % but a very high negative predictive value 
of  >94  % when compared to microscopy. The positive 
predictive value range was between 62.2  % (55.7–68.5) 
for SD Bioline 05FK50 kit to 68.8  % (62.2–74.8) for 
BinaxNOW kit. The highest negative predictive value 
was 96.79  % (92.8–98.6) for the SD Bioline 05FK50 kit. 
The positive likelihood ration range was 3.5–4.4 while the 
negative likelihood ratio range was 0.07–0.12 (Table 2).
The RDTs showed a moderate measure of agreement 
(>80  %) when compared to microscopy, the gold stand-
ard for malaria diagnosis (Table  2). The FDA-approved 
BinaxNOW 665-025 RDT had a higher per cent agree-
ment than the other RDTs: 83.4  % (κ  =  0.655). The 
majority of RDTs used in Kenya are CareStart, and all 
the three had almost the same measure of agreement; 
G0181 (82.0  %, κ  =  0.63), G0141 (81.6  %, κ  =  0.625) 
and G0131 (82.4  %, κ =  0.639). SD Bioline 05FK50 had 
80.08 % (κ =  0.597) and SD Bioline 05FK60 had almost 
the same 80.8 % (κ = 0.611). First Response I16FRC had 
82.8  % (κ =  0.642) while First Response I13FRC 82.2  % 
(κ = 0.635) (Table 2).
Density dependent sensitivity was observed across 
all the malaria RDTs. Parasite densities were classi-
fied into five groups according to microscopy posi-
tive results (n  =  166)  <200  P/µL (n  =  9), 200–500  P/
µL (n =  29), 500–2000 P/µL (n =  42), 2000–5000 P/µL 
(n = 29), >5000 P/µL (n = 38). At <200 P/µL (n = 9), the 
sensitivity ranged between 72 and 89  % and increased 
to  >93  % at 200–500  P/µL. At very high parasite densi-
ties >5000 P/µL, all the RDTs had 100 % sensitivity indi-
cating their ability to correctly detect P. falciparum in 
patient with high levels of the parasite (Table 3).
Performance of eight malaria RDTs as compared to RT‑PCR 
as the reference test
The performance of the RDTs to detect P. falciparum 
when compared to RT-PCR was similar across all the 
kits but quite different from microscopy. The sensitivity 
Table 1 Results for  Giemsa microscopy, RT-PCR 
and  malaria RDTs for  the detection of  Plasmodium para-
sites
Method Positive, N (%) Negative, N (%)
Giemsa microscopy 166 (33) 334 (67)
RT-PCR 256 (51) 244 (49)
BinaxNOW 665-025 221 (44) 269 (54)
SD Bioline 05FK60 240 (48) 260 (52)
SD Bioline 05FK50 233 (48) 248 (52)
First Response I16FRC 220 (44) 280 (56)
First Response I13FRC 231 (46) 269 (54)
CareStart G0131 232 (46) 268 (54)
CareStart G0181 230 (46) 270 (54)
CareStart G0141 236 (47) 264 (53)
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ranged from 71.1  % (65.1–76.6  %) for First Response 
I16FRC to 75.4  % (69.6–80.5  %) for SD Bioline 05FK60 
and CareStart G0181. The specificity of all the kits 
was  >80  % when compared to PCR results. The highest 
specificity was 84.8 % (79.7–89.1 %) for BinaxNOW while 
lowest specificity was 80.8  % (75.2–85.6  %) for SD Bio-
line 05FK50. Unlike when compared to microscopy, the 
positive predictive values for the eight RDTs was >83.3 % 
while the negative predictive value was low at  >73.6  %. 
The positive predictive values ranged from 80.3 % (74.6–
85.2 %) for SD Bioline 05FK50 to 83.3 % (77.7–87.9 %) for 
BinaxNOW. The negative predictive values ranged from 
73.6 % (68.0–78.6 %) for First Response I16FRC to 76.1 % 
(70.5–81.2 %) for SD Bioline 05FK60. The positive likeli-
hood ratio ranged between 3.9 and 4.7 while the negative 
likelihood ratio was at 0.3. The RDTs showed a moder-
ate measure of agreement (>77 %) when compared to RT-
PCR as a more sensitive reference method. CareStart had 
the higher agreement value of 78.8 % while First Response 
had the lower agreement of 77.6 %. All the RDTs had a 
relative agreement with PCR at κ > 0.6 (Table 4).
Discussion
In this study, the performance of different RDT kits 
(BinaxNow, First Response, CareStart, and SD Bioline) 
was evaluated using 500 samples from febrile patients 
(n  =  500). This study reproduces the actual perfor-
mance these RDTs would be expected to provide under 
real-world field conditions, complexities and physical 
stresses. Sensitivities of these kits was shown to be >90 %, 
specificities were shown to be >73 %, PPV was shown to 
be >62 %, and NPV was shown to be >94 %, and >80 % 
agreement with microscopy was shown by these RDT 
assays. The data from this study are consistent with other 
published work when RDTs are compared to microscopy. 
For example, a study in Central Africa Republic showed 
that SD Bioline antigen (HRP2) had a sensitivity range 
of 88.1–95.4 %, specificity range of 76.2–87.2 %, PPV of 
0.8–89.8, and a NPV of 85.0–94.1 [17]. A study by Maltha 
et al. [18], in a reference setting showed the sensitivity of 
the CareStart Malaria HRP-2/pan kit for the detection of 
P. falciparum to be 84.8–92.0 %.
Field and laboratory evaluations in India for the First 
Response malaria antigen HRP2/pan kit showed a sensi-
tivity ranging from 89.5 to 97.7 % and specificity ranging 
from 63.6 to 75.6  % for detection of P. falciparum [19]. 
A study conducted in a health centre in Dindori, India, 
which is a highly malaria-endemic area, examining First 
Response demonstrated the sensitivity of range from 
89.5 to 97.7  % and specificity from 63.6 to 75.6  %, with 
PPV ranging from 56.5 to 70.3 %, NPV ranging from 91.9 
to 98.4 %, and an agreement with microscopy of 78.8 % 
(κ-0.58) [20].
The sensitivity of RDTs in this study was shown to 
increase with increase in parasite density. This implies 
the inability of RDTs to reliably detect malaria parasites 
at very low parasites densities. Performance of BinaxNow 
in a large field trial by Gasser et  al. showed an overall 
Table 2 Performance comparison of malaria RDTs against Giemsa microscopy for the detection of Plasmodium falciparum
CI confidence interval, RDTs Rapid diagnostic test

















91.6 79.3 68.8 94.9 4.4 0.1 83.4 0.7
86.3–95.3 74.6–83.6 62.2–74.8 91.7–97.2 3.6–5.5 0.1–0.2 0.6–0.7
SD Bioline 
05FK60
93.4 74.6 64.6 95.8 3.7 0.1 80.8 0.6
88.5–96.6 69.5–79.1 58.2–70.6 92.6–97.9 3.0–4.4 0.1–0.2 0.5–0.6
SD Bioline 
05FK50
94.8 73.3 62.2 96.8 3.5 0.1 80.1 0.6
89.9–97.7 68.1–77.9 55.7–68.5 93.8–98.6 2.9–4.3 0.0–0.1 0.5–0.6
First Response 
I16FRC
90.3 79.0 68.2 94.3 4.3 0.1 82.8 0.6
84.8–94.4 74.3–83.3 61.6–74.3 90.9–96.7 3.5–5.3 0.1–0.2 0.5–0.6
First Response 
I13FRC
92.8 76.9 66.7 95.5 4.0 0.1 82.2 0.6
87.7–96.2 72.1–81.4 60.2–72.2 92.3–97.7 3.3–4.9 0.1–0.2 0.5–0.6
CareStart 
G0131
93.4 76.9 66.81 95.9 4.0 0.1 82.4 0.6
88.5–96.6 72.1–81.4 60.4–72.8 92.8–97.9 3.3–4.9 0.1–0.2 0.5–0.6
CareStart 
G0181
92.2 76.9 66.5 95.2 4 0.1 82.0 0.6
86.9–95.8 72.1–81.4 60.0–72.6 91.9–97.4 3.3–4.9 0.1–0.2 0.5–0.6
CareStart 
G0141
93.4 75.8 65.7 95.8 3.9 0.1 81.6 0.6
88.5–96.6 70.8–80.3 59.2–71.7 92.7–97.9 3.2–4.7 0.1–0.2 0.5–0.6
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sensitivity of 95  % for detection of P. falciparum, how-
ever, stratified P. falciparum sensitivity calculations indi-
cated a sensitivity of 93  % (P. falciparum  >500–1000/
µL), 89 % (P. falciparum >100–500/µL), and 54 % (P. fal-
ciparum  >0–100/µL) [21]. An evaluation of BinaxNow 
in Toronto General Hospital, Canada on 256 patients 
travelling from malaria-endemic countries showed that 
BinaxNow had a sensitivity of 96 % for infections with a 
parasite density >100/µL but decreased to 75 % for densi-
ties <100/µL when compared to microscopy [22].
The WHO recommends that RDTs should have a sensi-
tivity of >95 % and a specificity of >90 % [8], and the eval-
uated RDTs demonstrated a relatively strong sensitivity 
ranging from 90.36 to 94.77 %. Hence, they can be con-
sidered as clinically useful diagnostic tools for ruling out 
malaria. BinaxNow was tested in another study at the 
bedside and in the clinical laboratory for diagnosis of 
malaria in 542 patients by Wiese et al. [23] and the sen-
sitivity was shown to be 88 % at the bedside and 95 % in 
the laboratory. Importantly, the difference in sensitivity 
between assays at the bedside and in the laboratory may 
explain why field diagnosis can show a lower sensitivity 
than recommended by the WHO.
The relatively high sensitivity demonstrated in this 
study decreased the likelihood of RDTs incorrectly 
identifying a patient as a false negative, hence showing 
Table 3 Sensitivity of malaria RDTs as compared to Giemsa Microscopy classified by parasite densities











BinaxNOW 665-025 (%) 79 93 90 96 100
SD Bioline 05FK60 (%) 86 93 93 96 100
SD Bioline 05FK50 (%) 89 96 100 100 100
First Response I16FRC (%) 72 93 90 96 100
First Response I13FRC (%) 83 93 93 96 100
CareStart G0131 (%) 86 93 93 96 100
CareStart G0181 (%) 86 93 88 96 100
CareStart G0141 (%) 83 93 93 100 100
Table 4 Performance comparison of malaria RDTs against RT-PCR for the detection of Plasmodium falciparum


















71.9 84.8 83.3 74.2 4.7 0.3 78.2 0.6
65.9–77.3 79.7–89.1 77.7–87.9 68.6–79.2 3.5–6.4 0.3–0.4 0.5–0.6
SD Bioline 
05FK60
75.4 81.1 80.4 76.1 3.9 0.3 78.0 0.6
69.6–80.5 75.6–85.7 74.8–85.2 70.5–81.2 2.9–5.1 0.3–0.4 0.5–0.6
SD Bioline 
05FK50
74.8 80.8 80.3 75.4 4.0 0.3 79.0 0.6
68.9–80.5 75.2–85.6 74.6–85.2 69.6–80.54 3.1–5.3 0.3–0.4 0.5–0.7
First Response 
I16FRC
71.1 84.4 82.7 73.6 4.6 0.3 77.6 0.6
65.1–76.6 79.3–88.7 77.1–87.5 68.0–78.6 3.4–6.2 0.3–0.4 0.5–0.6
First Response 
I13FRC
73.8 82.8 81.8 75.1 4.3 0.3 78.2 0.6
67.9–79.1 77.5–87.3 76.2–86.6 69.4–80.1 3.2–5.7 0.3–0.4 0.5–0.6
CareStart 
G0131
73.8 82.4 81.5 75.0 4.2 0.3 78.0 0.6
67.9–79.1 77.0–86.9 75.7–86.3 69.4–80.1 3.2–5.5 0.3–0.4 0.5–0.6
CareStart 
G0181
72.3 81.6 80.4 73.7 3.9 0.3 76.8 0.6
66.4–77.7 76.1–86.2 74.7–85.4 68.0–78.9 2.9–5.2 0.3–0.4 0.5–0.6
CareStart 
G0141
75.4 82.4 81.8 76.1 4.3 0.3 78.8 0.5
69.6–80.5 77.0–86.9 76.3–86.5 70.5–81.2 3.2–5.7 0.3–0.4 0.5–0.6
Page 8 of 10Wanja et al. Malar J  (2016) 15:456 
a substantive ability to identify patients who truly had 
malaria. A cross-sectional study conducted in Blantyre 
District in Malawi assessed the performance of HRP2 
RDTs (SD Bioline Malaria, First Response, Paracheck, 
ICT Malaria,) and overall, there were 44/633 (7 %) false-
negative RDT results compared to microscopy [24].
The results showed a lower specificity as compared 
to WHO-recommended specificity of an effective RDT, 
and this is probably due to prior infection and subse-
quent effective treatment. The exclusion criteria included 
malaria treatment within the previous 2 weeks; some par-
ticipants may have been treated for malaria; however the 
HRP-2 detected by these RDTs may have persisted in the 
blood stream before being completely cleared from the 
blood. A persistent parasite antigenaemia of HRP-2 has 
been demonstrated; a study on 240 patients with P. falci-
parum mono-infection was done after anti-malarial treat-
ments using ICT malaria and optimal-IT assays; 82.1 % of 
the patients demonstrated persistent antigenaemia for the 
HRP2 antigen up to 14 days of follow-up [25]. Others stud-
ies have shown that that it can last for up-to 28 days while 
others suggest that it has a median of 20 days [26, 27]. The 
second explanation for the high rate of false-positive RDT 
results may be due to malaria cases with parasite densities 
below the detection level of microscopy. Examination of 
the blood slides by microscopy may not detect the parasites 
due to very low parasitaemia, but the RDTs may test posi-
tive because they detect antigens from the parasites [28].
The disease prevalence in this endemic Lake Victoria 
region is known to be approximately 37  % [9]. Evalua-
tions of the 500 participants indicated a prevalence of 
33 %, making the positive and negative predictive values 
significant. The high NPV shown (>94  %) in this study 
will lead to RDTs being used with confidence to confirm 
negative test patients as non-malaria patients. The risk of 
missing detectable malaria parasites in an infected indi-
vidual is small for all the RDTs evaluated [20]. Although 
the test performances of the RDTs were characterized by 
low PPVs which indicates over-diagnosis this can pro-
duce high estimates of malaria morbidity, inflate treat-
ment costs, and create misperceptions of therapeutic 
failures when fever is due to other illness. This may lead 
to avoidable, drug-related, adverse events and contribute 
to unnecessary drug pressure, thereby enhancing selec-
tion or drug resistance [3]. There was a small increase 
(a range of 3.54–4.43) in the likelihood of a positive test 
result in participants who had malaria compared to par-
ticipants who did not have malaria. There was a moderate 
to large decrease (a range of 0.12–0.07) in the likelihood 
of a negative result in participants who had the disease 
compared to those without the disease.
The performance of RDTs compared to PCR was 
quite different than when compared to microscopy. 
The sensitivity of RDTs was lower at 71.1–75.4 % when 
compared to PCR but >90 % when compared to micros-
copy. The specificity of RDTs in our results is almost 
similar other studies [18, 29–31]. This indicates that the 
ability of the RDTs to detect malaria positive individu-
als is heightened when compared to microscopy sim-
ply because they have almost a similar detection limit 
(100 P/µL). A more sensitive method, PCR has the capa-
bility of detecting parasites as low as 0.002 P/µL imply-
ing that lower sensitivity range observed could be due 
to submicroscopic infections in the population. Indi-
viduals with submicroscopic infections can significantly 
contribute to plasmodium transmission dynamics by 
acting as human infectious reservoirs [32, 33]. The lev-
els of infections are known to vary due to several rea-
sons that correlate with malaria transmission intensity. 
These factors include the mosquito population which 
accelerate the rates of re-infection, acquired immunity 
after living in a malaria endemic regions, multiplicity of 
clonal subtypes of the parasite, and partially successful 
treatments [32].
The opposite was observed for specificity whereby the 
levels were higher when compared to PCR (80.8–84.8 %) 
than microscopy (73.3–79.3 %). The specificity of RDTs 
in our results is almost similar other studies [18, 29–31]. 
This indicates that the when compared the PCR; they 
have a higher ability to actually detect a malaria nega-
tive patient. As the malaria prevalence decreases [1], 
the ability of the diagnostic tools to correctly identify a 
malaria negative individual will be more relevant. This 
will also be important in low transmission areas where 
accurately identifying the presence of malaria para-
sites ensures accurate treatment with ACT [33] while 
absence of the disease ensures the correct diagnosis of 
the underlying disease. The errors associated with RDTs 
such as false positives, false negatives, inability to detect 
submicroscopic infections, persistent antigenaemia of 
HRP2, and polymorphisms of HRP2, will require PCR 
to complement their usage at the point of care [5, 8, 
28]. This is because PCR has the ability to discriminate 
very low parasite density results, it can detect persistent 
antigenaemia, and it has very high sensitivity and speci-
ficity [6].
Conclusion
Rapid diagnostic tests can be applied in a number of set-
tings with a great potential for impact on public health 
where they can significantly improve the quality of 
malaria case management in areas where expert micros-
copy or PCR methods are not available. This study dem-
onstrated that CareStart, SD Bioline, BinaxNow, and 
First Response RDTs performed reasonably well in this 
endemic region for the detection of P. falciparum. More 
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evaluations should be carried out around the country, 
particularly in non-endemic areas with returning migrant 
workers from endemic areas as well as in epidemic high-
land areas. After implementation and deployment of 
RDTs in health facilities, subsequent research should be 
done on their impact and cost effectiveness in providing 
reliable diagnosis at the point of care.
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